Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterizing the Specificity and Sensitivity of Oral TTMV-HPV DNA Testing: The SPOT-HPV Study

NCT05524025 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT05524025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05524025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterizing the Specificity and Sensitivity of Oral TTMV-HPV DNA Testing: The SPOT-HPV Study
Lead sponsor
Dana-Farber Cancer Institute
Phase
Observational
Overall status
Completed
Start date
November 30, 2022
Completion date
January 1, 2026
Enrollment
360 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hpv infection, hpv positive oropharyngeal squamous cell carcinoma